Complementary and alternative medicine: Opportunities and challenges for cancer management and research

Seminars in Oncology

Volumn 29, Issue 6, 2002, Pages 531-545

  Richardson, Mary Ann ^a   Straus, Stephen E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOE VERA EXTRACT; ANTIOXIDANT; ENZYME; GARLIC EXTRACT; GINSENG EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; HYDRAZINE SULFATE; HYPERICUM PERFORATUM EXTRACT; SELENIUM; THYMUS EXTRACT; VACCINE; VISCUM ALBUM EXTRACT;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RESEARCH; CANCER THERAPY; DOCTOR PATIENT RELATION; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAFETY; TREATMENT OUTCOME;

EID: 0036968184     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.50002     Document Type: Article

References (116)

1. The National Center for Complementary and Alternative Medicine: Expanding Horizons of Healthcare: The Five-Year NCCAM Strategic Plan 2001-2005. http://NCCAM. Nih.Gov/Nccam/Strategic, accessed March 28, 2001
2. Arab L: Epidemiologic challenges in the study of the efficacy and safety of medicinal herbs. Public Health Nutr 3:453-457, 2000
3. Eisenberg D, Davis R, Ettner S, et al: Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 280:1569-1575, 1998
4. Eisenberg D, Kessler RC, Foster C, et al: Unconventional medicine in the United States: Prevalence, costs, and patterns of use. N Engl J Med 328:246-252, 1993
5. Wolsko P, Eisenberg D, Davis R, et al: Insurance coverage, medical conditions, and visits to alternative medicine providers: Results of a national survey. Arch Intem Med 162:281-287, 2002
6. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer. A systematic review. Cancer 83:777-782, 1998
7. Kelly KM, Jacobson JS, Kennedy DO, et al: Use of unconventional therapies by children with cancer at an urban medical center. J Pediatr Hematol Oncol 22:412-426, 2000
8. Richardson MA, Ramirez T, Palmer JL, et al: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505-2514, 2000
9. Lee MM, Lin SS, Wrensch MR, et al: Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42-47, 2000
10. Crocetti E, Crotti N, Feltrin A, et al: The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer 34:324-328, 1998
11. Munstedt K, Kirsch K, Milch W, et al: Unconventional cancer therapy: Survey of patients with gynecological malignancy. Arch Gynecol Obstet 258:81-88, 1996
12. Burstein HJ, Gelber S, Guadagnoli E, et al: Use of alternative medicine by women with early-stage breast cancer. JAMA 340:1773-1739, 1999
13. Verhoef MJ, Hagen N, Pelletier G, et al: Alternative therapy use in neurologic diseases. Neurology 52:617-622, 1999
14. Adler SR, Foskett JR: Disclosing complementary and alternative medicine use in the medical encounter: A qualitative study in women with breast cancer. J Fam Pract 48:453-458, 1999
15. Boon H, Stewart M, Kennard M, et al: Use of complementary/alternative medicine by breast cancer survivors in ontario: prevalence and perceptions. J Clin Oncol 18:2515-2521, 2000
16. Lippert M, McClain R, Boyd J, et al: Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 86:2642-2648, 1999
17. Sollner W, Maislinger S, DeVries A, et al: Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior. Cancer 89:873-880, 2000
18. Rees R, Feigel I, Vickers A, et al: Prevalence of complementary therapy use by women with breast cancer: A population-based survey. Eur J Cancer 36:1359-1364, 2000
19. Moschen R, Kemmler G, Schweigkofier H, et al: Use of alternative/complementary therapy in breast cancer patients - A psychological perspective. Support Care Cancer 9:267-274, 2001
20. Gotay C, Hara W, Issell B, et al: Use of complementary and alternative medicine in Hawaii cancer: patients. Hawaii Med J 58:94-95, 1999
21. Sparber A, Bauer L, Curt G, et al: Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 27:623-630, 2000
22. Weis J, Bartsch H, Hennies F, et al: Complementary medicine in cancer patients: Demand, patients' attitude, and psychological belief. Onkologie 21:144-149, 1998
23. Risberg T, Lund E, Wist E, et al: The use of non-proven therapy among patients treated in Norwegian oncological departments: A cross-sectional national multicenter study. Eur J Cancer 31A:1785-1789, 1995
24. Begbie SD, Kerestes ZL, Bell DR: Patterns of alternative medicine use by cancer patients. Med J Aust 165:545-548, 1996
25. Sollner W, Zingg-Schir M, Rumpold G, et al: Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma. Arch Dermatol 133:316-321, 1997
26. Fernandez CV, Stutzer CA, MacWilliam L, et al: Alternative and complementary therapy use in pediatric oncology patients in British Columbia: Prevalence and reasons for use and nonuse. J Clin Oncol 16:1279-1286, 1998
27. Sawyer MG, Gannoni AF, Toogood IR, et al: The use of alternative therapies by children with cancer. Med J Aust 160:320-322, 1994
28. Oneschuk D, Fennell L, Hanson J, et al: The use of complementary medications by cancer patients attending an outpatient pain and symptom clinic. J Palliat Care 14:21-26, 1998
29. Lerner IJ, Kennedy BJ: The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin 42:181-191, 1992
30. DiPaola RS, Zhang H, Lambert GH, et al: Clinical and biologic activity of an estrogenic herbal combination (PCSPES) in prostate cancer. N Engl J Med 339:785-791, 1998
31. Ernst E: Harmless herbs? A review of the recent literature. Am J Med 104:170-178, 1998
32. Labriola D, Livingston R: Possible interactions between dietary antioxidants and chemotherapy. Oncology 19:1003-1008, 1999
33. Lamson D, Brignall M: Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 4:304-329, 1999
34. Weijl NI, Cleton FJ, Osanto S: Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209-240, 1997
35. Zeisel S, Salganik R: Special commentary: Antioxidants and nutrition support. Curr Opin Clin Nutr Metab Care 2:1-3, 1999
36. Conklin K: Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37:1-18, 2000
37. Washburn A: Complementary therapies: A survey of NCI cancer patient educators. Cancer Pract 8:143-144, 2000
38. Slevin ML, Stubbs L, Plant HJ, et al: Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 300:1458-1460, 1990
39. Jeffrey D: Education in palliative care: A qualitative evaluation of the present state and the needs of general practitioners and community nurses. Eur J Cancer Care (Engl) 3:67-74, 1994
40. Stoll BA: Can unorthodox cancer therapy improve quality-of-life? Ann Oncol 4:121-123, 1993
41. Pan C, Morrison R, Ness J, et al: Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life: a systematic review. J Pain Symptom Manage 20:374-387, 2000
42. Wallace KG: Analysis of recent literature concerning relaxation and imagery interventions for cancer pain. Cancer Nurs 20:79-87, 1997
43. Tagliaferri M, Cohen I, Tripathy D: Complementary and alternative medicine in early-stage breast cancer. Semin Oncol 28:121-134, 2001
44. NIH Consensus Development Panel on Acupuncture: Acupuncture. JAMA 280:1518-1524, 1998
45. Shen J, Wenger N, Glaspy J, et al: Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA 284:2755-2761, 2000
46. Richardson MA, Allen C, Ezzo J, et al: Acupuncture for chemotherapy induced nausea and vomiting in cancer patients (Protocol for a Cochrane Review), in: The Cochrane Library, issue 3, 2002. Oxford, UK, Update Software
47. McMillan CM, Dundee JW: The role of transcutaneous electrical stimulation of Neiguan anti-emetic acupuncture point in controlling sickness after chemotherapy. Physiotherapy 77:499-502, 1991
48. Schneider K, Leonard E: A matter of choice. People, April 30, 2001, pp 72-81
49. Bussing A: Mistletoe: A story with an open end. Anticancer Drugs 8:S1-S2, 1997 (suppl)
50. Hajto T, Hostanska K, Gabius HJ: Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49:4803-4808, 1989
51. Hajto T, Hostanska K, Frei K, et al: Increased secretion of tumor necrosis factor alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to b-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50:3322-3326, 1990
52. Schultze JL, Stettin A, Berg PA: Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.). Klin Wochenschr 69:397-403, 1991
53. Muller EZ, Anderer FA: A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother 32:221-227, 1990
54. Kleijnen J, Knipschild P: Mistletoe treatment for cancer. Review of controlled clinical trials. Phytomedicine 1:255-260, 1994
55. Kaegi E: Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158:1157-1159, 1998
56. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial. Eur J Cancer 37:23-31, 2001
57. Kleeberg U, Brocker E, Lejeune F, et al: Adjuvant trial in melanoma patients comparing rIFN-alpha to rIFN-gamma to Iscador to a control group after curative resection of high-risk primary or regional lymph node metastasis (EORTC 18871). Eur J Cancer 35:S82, 1999 (suppl 4, abstr 264)
58. Grossarth-Maticek R, Kiene H, Baumgartner S, et al: Use of Iscador, an extract of European mistletoe (viscum album), in cancer treatment: Prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 7:57-78, 2001
59. Marks LS, Di Paola RS, Nelson D, et al: PC-SPES: Herbal formulation for prostate cancer. Urology 60:369-377, 2002
60. Darzynkiewicz Z, Traganos F, Wu J, et al: Chinese herbal mixture PC SPES in treatment of prostate cancer. Int J Oncol 17:729-736, 2000
61. de la Taille A, Hayek O, Buttyan R, et al: Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: A preliminary investigation on human cell lines and patients. BJU Int 84:845-850, 1999
62. Pfeifer B, Pirani J, Hamann S, et al: PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 85:481-485, 2000
63. Small E, Frohlich M, Bok R, et al: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595-3603, 2000
64. Sun AS, Ostadal O, Ryznar V, et al: Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer 34:62-69, 1999
65. Sun A, Yeh H, Wang L, et al: Pilot study of a specific dietary supplement in tumor bearing mice and in stage IIIB and IV non-small cell lung cancer patients. Nutr Cancer 39:85-95, 2001
66. King LS: Prevention of virus-induced mammary tumors by an orally active pancreas factor. Exp Med Surg 23:345-347, 1965
67. King LS: A novel method of enhancing antibody production. Southwest Med 46:222-224, 1967
68. US Congressional Office of Technology Assessment. Washington, DC: US Government Printing Office, 1990
69. Gonzalez NJ, Isaacs LL: Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutriton and detoxification support. Nutr Cancer 32:117-124, 1999
70. Niederhuber JE, Brennan MF, Menck HR: The national cancer data base report on pancreatic cancer. Cancer 76:1671-1677, 1995
71. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
72. National Institutes of Health: Gemcitabine compared with pancreatic enzyme therapy in treating patients who have stage II, stage III, or stage IV pancreatic cancer. August 1, 2000; accessed May 8, 2001. Web Page. Available at: http://www. clinicaltrials.gov
73. Frichtel H: Chemotherapy with or without Wobe-Mugos E in treating patients with stage II or stage III multiple myeloma. Personal Communication, Medsearch, October 22, 2002
74. Klaschka F: Oral Enzymes - New Approach to Cancer Treatment: Immunological Concepts for General and Clinical Practice. Grafelfing, Germany: Forum-Mendizin Verlagsgesellschaft mbH, 1996
75. Sakalova A, Dedik L, Gazova S, et al: Survival analysis of an adjuvant therapy with oral enzymes in multiple myeloma patients. Br J Haematol 102:353, 1998 (suppl 5)
76. Sakalova A, Desser L, Bucova M, et al: Recent immunological approaches and therapy of multiple myeloma. J Health Manage Public Health 3:47-54, 1998
77. Sakalova A, Chabronova I, Gazova S, et al: Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol 47:S38-44, 2001 (suppl)
78. Buiatti E, Amiani S, Verdecchia A, et al: Results from a historical survey of the survival of cancer patients given Di Bella multitherapy. Cancer 86:2143-2149, 1999
79. Italian Study Group for the Di Bella Multitherapy Trials: Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): Results of phase II trials in Italy. BMJ 318:224-228, 1999
80. Ness C: Alternative Therapy for Cancer Welcomed. San Francisco Examiner-Chronicle, October 25, 1998, p (D)1
81. Richardson MA, Tamayo C, Klein A, et al: Rationale for drug development of herbals in oncology: Clinical, industry, and regulatory perspectives. Drug Info J 33:1003-1010, 1999
82. Lazarowych N, Pekos P: Use of fingerprinting and marker compounds for identification and standardization of botanical drugs: Strategies for applying pharmaceutical HPLC analysis to herbal products. Drug Info J 32:497-512, 1998
83. Houghton PJ: Establishing identification criteria for botanicals. Drug Info J 32:461-469, 1998
84. Kaptchuk TJ: Chinese herbal medicine for irritable bowel syndrome. JAMA 282:1035-1047, 1999
85. Jadad A, Gagliardi A: Rating health information on the internet. JAMA 279:611-614, 1998
86. Ernst E, Armstrong N: Lay books on complementary/alternative medicine: A risk factor for good health? Int J Risk Safety Med 11:209-215, 1998
87. Ezzo J, Berman B, Vickers A, et al: Complementary medicine and the Cochrane Collaboration. JAMA 280:1628-1630, 1998
88. Voelker R: CAM research attempts to separate wheat from chaff. JAMA 286:156-158, 2001
89. Ernst E: The Desktop Guide to Complementary and Alternative Medicine: An Evidence-Based Approach. New York, NY, Mosby, 2001
90. Fontanarosa PB: Alternative medicine meets science. JAMA 280:1618-1619, 1998
91. Angell M, Kassirer P: Alternative medicine - The risks of untested and unregulated remedies. N Engl J Med 339:839-841, 1998
92. Tannock IF, Warr DG: Unconventional therapies for cancer: A refuge from the rules of evidence? Can Med Assoc J 159:801-802, 1998
93. Holland JC, Geary N, Furman A: Alternative cancer therapies, in Holland JC, Rowland JH (eds): Handbook of Psychooncology: Psychological Care of the Patient With Cancer. New York, NY, Oxford University Press, 1989, pp 508-515
94. Cassileth BR: Unorthodox cancer medicine. Cancer Invest 4:591-598, 1986
95. Vickers A, Cassileth B, Ernst E, et al: How should we research unconventional therapies - A panel report from the Conference on Complementary and Alternative Medicine Research Methodology, National Institutes of Health. Intern J Technol Assess Health Care 13:111-121, 1997
96. Levin JS, Glass TA, Kushi LH, et al: Quantitative methods in research on complementary and alternative medicine: a methodological manifesto. Med Care 35:1079-1094, 1997
97. Margolin A, Avants SK, Kleber HD: Investigating alternative medicine therapies in randomized controlled trials. JAMA 280:1626-1628, 1998
98. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 75:4538-4542, 1978
99. Cameron E, Pauling L: Cancer and Vitamin C. Menlo Park, CA: Linus Pauling Institute of Science and Medicine, 1979
100. Creagan ET, Moertel CG, O'Fallon JR, et al: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301:687-690, 1979
101. Moertel CG, Fleming TR, Creagan ET, et al: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312:137-141, 1985
102. Loprinzi CL, Kuross SA, O'Fallon JR, et al: Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 12:1121-1125, 1994
103. Kosty MP, Fleishman SB, Herndon JE II, et al: Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-smallcell lung cancer: A randomized placebo-controlled, doubleblind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 12:1113-1120, 1994.
104. Herndon JE II, Fleishman S, Kosty MP, et al: A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials 18:286-300, 1997
105. Chlebowski RT, Bulcavage L, Grosvenor M, et al: Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol 8:9-15, 1990
106. Hawkins MG, Friedman MA: National Cancer Institute's evaluation of unconventional cancer treatments. J Natl Cancer Inst 74:1699-1702, 1992
107. Ernst E: Editorial comment: Mistletoe for cancer? Eur J Cancer 37:9-11, 2001
108. Balmer C: Alternative therapies in cancer patient care. Highlights Oncol Pract 15:83-93, 1998
109. American Cancer Society: American Cancer Society's Guide to Complementary and Alternative Cancer Methods. Atlanta, GA: American Cancer Society, 2000
110. The University of Texas M.D. Anderson Cancer Center. Available at: http://www.mdanderson.org/departments/cimer, accessed October 20, 2002
111. Kappauf H, Leykauf-Ammon D, Bruntsch U, et al: Use of and attitudes held towards unconventional medicine by patients in a department of internal medicine/oncology and haematology. Support Care Cancer 8:314-322, 2000
112. Morris K, Johnson N, Horner L, et al: A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179:407-411, 2000
113. Ashikaga T, Bosompra K, O'Brien P, et al: Use of complementary and alternative medicine by breast cancer patients: Prevalence, patterns and communication with physicians. Support Care Cancer (in press)
114. McCurdy E, Spangler J, Wofford M, et al: Complementary and alternative therapy use in pediatric oncology patients. J Pediatr Hematol Oncol A27, 2001
115. Powell C, Dibble S, Dall'era J, et al: Use of herbs in women diagnosed with ovarian cancer. Int J Gynecol Cancer 12:214-217, 2002
116. Von Gruenigen V, White L, Kirven M, et al: A comparison of complementary and alternative medicine use by gynecology and gynecologic oncology patients. Int J Gynecol Cancer 11:205-209, 2000